Drugs / human gp100 plasmid DNA vaccine
last change Sep 2011 re-read 3 minutes ago

human gp100 plasmid DNA vaccine

Vaccine

Developed for
cutaneous melanoma
Investigated by
Memorial Sloan Kettering Cancer Center · National Cancer Institute (NCI)

Trials 1

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00104845 Sep 2004 → Sep 2011 cutaneous melanoma Memorial Sloan Kettering Cancer Center Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as human gp100 plasmid DNA vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00104845 ↗
Modality Vaccine “human gp100 DNA vaccine” NCT00104845 ↗
Route Intramuscular “Patients receive human gp100 DNA vaccine intramuscularly (IM)” NCT00104845 ↗